{"id":"NCT01419717","sponsor":"Amgen","briefTitle":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","officialTitle":"Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-22","primaryCompletion":"2018-08-10","completion":"2018-08-10","firstPosted":"2011-08-18","resultsPosted":"2019-09-09","lastUpdate":"2019-09-24"},"enrollment":129,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bone Metastases in Men With Hormone-Refractory Prostate Cancer","Bone Metastases in Subjects With Advanced Breast Cancer"],"interventions":[{"type":"DRUG","name":"Denosumab","otherNames":["Xgeva"]}],"arms":[{"label":"Denosumab","type":"EXPERIMENTAL"}],"summary":"This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose of denosumab in Study 20110113 to end of study; median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.","effectByArm":[{"arm":"Denosumab","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":64,"countries":["Argentina","Austria","Belgium","Brazil","Czechia","France","Hungary","Israel","Italy","Japan","Latvia","Lithuania","Panama","Peru","Poland","Russia","South Africa","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":45,"n":128},"commonTop":["Back pain","Nausea","Asthenia","Arthralgia","Decreased appetite"]}}